Icon

REZUROCK (nda214783)- (EQ 200MG BASE)

BELUMOSUDIL MESYLATE KADMON PHARMS LLC
EQ 200MG BASE
No No
2035-Apr-09 2026-Jul-16
None None
None No
REZUROCK is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
0 0 0
Total Other Developers 9
Drugs with Suitability No
EQ 200MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.